AstraZeneca's Saphnelo meets primary endpoint in TULIP-SC trial for systemic lupus erythematosus
The biopharmaceutical company reports that its Saphnelo treatment met the primary endpoint in a Phase III trial for systemic lupus erythematosus, demonstrating a statistically significant and clinically meaningful reduction in disease activity.